Search results
Results from the WOW.Com Content Network
Stopping imipramine (Tofranil), paroxetine (Paxil or Seroxat), and venlafaxine (Effexor)/ desvenlafaxine (Pristiq) was associated with a higher risk of severe symptoms compared to other ...
[2] [6] [4] Treatment may include restarting the medication and slowly decreasing the dose. [2] People may also be switched to the long-acting antidepressant fluoxetine which can then be gradually decreased. [6] Approximately 15–50% of people who suddenly stop an antidepressant develop antidepressant discontinuation syndrome.
Patients who wish to come off the drugs permanently should first agree with their doctor whether it is right to stop taking the medication, and, if so, the speed and duration of withdrawal from it ...
Desvenlafaxine is a synthetic form of the isolated major active metabolite of venlafaxine, and is categorized as a serotonin-norepinephrine reuptake inhibitor (SNRI). When most normal metabolizers take venlafaxine, approximately 70% of the dose is metabolized into desvenlafaxine, so the effects of the two drugs are expected to be very similar. [18]
About 15% of people who stop taking antidepressants may experience withdrawal symptoms, according to a new study.
Venlafaxine, sold under the brand name Effexor among others, is an antidepressant medication of the serotonin–norepinephrine reuptake inhibitor (SNRI) class. [6] [9] It is used to treat major depressive disorder, generalized anxiety disorder, panic disorder, and social anxiety disorder. [9]
Some side effects, such as weight gain, occur more frequently with certain types of antidepressant medication. Switching to a new type of antidepressant may help reverse any weight gain you’ve ...
Headache — an often transient side effect that is common to most serotonin reuptake inhibitors and that most often occurs at the beginning of therapy or after a dose escalation. Nausea — an adverse effect that is more common with venlafaxine than with the SSRIs. Usually transient and less severe in those receiving the extended release ...